Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

22.03.2018 | review | Ausgabe 2/2018

memo - Magazine of European Medical Oncology 2/2018

JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2018
Autoren:
Soheila Bagheropur, Ali Ehsanpour, Maryam Tahmasebi Birgani, Najmaldin Saki
Wichtige Hinweise

Authors’ contributions

N. Saki conceived and revised the manuscript. S. Bagheropur, A. Ehsanpour and M.T. Birgani wrote the manuscript and prepared the tables.

Summary

Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are characterized by mutations in genes, such as JAK2V617F, JAK2 exon12 gene and MPL. With respect to MPN-associated subclasses, each of these disorders has a different allele burden during disease treatment. Up to now, several studies have been conducted on the relationship between allele burden with specific MPN-associated phenotypic features, prognosis and disease progression. It seems that finding such a correlation would be a great contribution to faster diagnosis and effective treatment. The goal of this review is to investigate the relationship between JAK2V617 allele burden with different MPN subtypes and their different phenotypes. Allele burden is closely associated with MPN phenotype and can partially indicate the prognosis, progression and even the likelihood of disease transformation.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2018

memo - Magazine of European Medical Oncology 2/2018 Zur Ausgabe